The dominant B2B news brand for biotech. Delivering news, revealing insights straight to your inbox.
Washington, DC
- Tweets 29,749
- Following 616
- Followers 102,711
- Likes 430
Genentech CEO talks Fierce through vision for the future fiercebiotech.com/biotech/no…
3
3,509
Lilly sets up next-gen obesity battle with full phase 3 retatrutide data fiercebiotech.com/biotech/el…
4
16
3,546
Amgen reveals 6-point drop in lupus severity behind phase 2 win for Horizon antibody fiercebiotech.com/biotech/am…
3
2
23
5,088
Zealand Pharma has shared primary endpoint data on Roche-partnered petrelintide, revealing that the middle dose of the amylin analog delivered the highest weight loss—9.8%—at Week 28. fiercebiotech.com/biotech/ro…
2
12
3,500
Novo’s ongoing attempts to rejuvenate its pipeline have seen the Big Pharma turn to one of the most in-demand drug developers in China. fiercebiotech.com/biotech/no…
3
7
3,555
AstraZeneca is investing $2 billion in Summit Therapeutics to accelerate the development of PD-1xVEGF bispecific ivonescimab in combination with antibody-drug conjugates. fiercebiotech.com/biotech/as…
1
1
15
3,640
uniQure’s Huntington’s disease gene therapy has failed to significantly slow disease progression after 48 months fiercebiotech.com/biotech/un…
1
7
3,487
Two of Kodiak Sciences’ drug candidates have matched Eylea in a phase 3 clinical trial, positioning the biotech to seek FDA approval of one of the eye disease assets this year. fiercebiotech.com/biotech/ko…
2
8
46
8,213
Tolerance Bio has continued to strengthen its thymus-focused pipeline by picking up an anti-IL-33 drug from Tanabe Pharma. fiercebiotech.com/biotech/to…
4
16
3,746
The Biomedical Advanced Research and Development Authority has awarded Scynexis with a $214 million contract for development of a treatment for invasive fungal infections. fiercebiotech.com/biotech/sc…
1
4
3,450
A phase 3 trial of Mirum Pharmaceuticals’ chronic hepatitis delta virus drug candidate has hit its primary endpoint, furthering the biotech’s efforts to enter a space recently colonized by Gilead Sciences. fiercebiotech.com/biotech/mi…
2
8
3,584
Daiichi and Merck withdrew an ADC filing after the FDA said they lacked the data for accelerated approval in a lung cancer population. fiercebiotech.com/biotech/me… $MRK
5
12
3,705
Celldex monoclonal antibody rebounds with a pair of phase 3 wins for chronic skin condition fiercebiotech.com/biotech/ce…
1
1
10
3,898
Novartis secures new radioligand in $900M deal fiercebiotech.com/biotech/no…
1
5
27
5,047
Boehringer Ingelheim and AI drug discovery company Envisagenics have agreed to a potential $1 billion multi-year pact that will task Boehringer with validating tumor-specific targets. fiercebiotech.com/biotech/bo…
4
20
3,929
Roche’s GLP-1/GIP drug hits in phase 2 diabetes trial, fueling best-in-disease hopes fiercebiotech.com/biotech/ro…
2
15
3,856
A phase 3 study of Otsuka and Ionis’ ALS prospect hit its primary endpoint, positioning the partners to talk to regulators about expedited approvals. fiercebiotech.com/biotech/ot…
1
4
17
4,458
Telix has struck a deal to buy ITM Isotope Technologies Munich for $1.65 billion upfront, securing an R&D pipeline led by a rival to Novartis’ Lutathera and a radiopharmaceutical supply network. fiercebiotech.com/biotech/an…
1
1
9
3,770
Following Takeda’s historic approval of the first orexin agonist with its narcolepsy treatment Orzeyful, Alkermes has followed up with pioneering data that looks to take the hyped drug class out of sleep disorders and into broader patient populations. fiercebiotech.com/biotech/pi…
3
2
14
3,925
China is aiming to account for at least 25% of first-in-class drugs as part of a five-year push to cement its emerging status in innovative R&D. fiercebiotech.com/biotech/ch…
1
4
8
3,617